How does tirzepatide work?
Tirzepatide is a dual GLP-1 and GIP receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. Mechanism combines satiety, gastric emptying, and glucose handling.
Full answer
Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. The dual mechanism produces greater weight loss than semaglutide in head-to-head comparisons — averaging 15-22% over 12-18 months in clinical trials — with similar glycemic benefit. The GIP axis contributes additional metabolic effects beyond what GLP-1 alone achieves. oMeds provider review requires the same baseline metabolic and renal workup as semaglutide, with recalibration cadence to monitor response, GI tolerability, and the lean-mass-preservation strategy that should accompany rapid weight loss.
Educational. Not a substitute for individualized provider review.
- Metabolic optimization — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29